The United States Food and Drug Administration has cleared a third COVID-19 vaccine for public use.
As expected on Saturday, Acting Commissioner Dr Janet Woodcock granted emergency use authorization for a vaccine developed by Janssen Pharmaceuticals, a Johnson & Johnson company.
About 4 million doses of the new vaccine are expected to be available next week, a total of 20 million in March and an additional 80 million by the end of June. Because the vaccine only requires one dose, it will help protect 100 million people and take effect more faster than two-dose vaccines.
The J&J vaccine joins two others, one from Pfizer-BioNTech and the other from Moderna, which have been administered to nearly 50 million Americans since their authorization in December.
Want to kiss you again? ‘Over to you’: New ad campaign gets straight to the point on COVID-19 vaccines
An FDA advisory committee voted on Friday to …
News Highlights Finance
- Headline: FDA clears Johnson & Johnson single-dose COVID vaccine, third in US
- Check all news and articles from the Health news information updates.